Factor Xa inhibitors, Era to replace traditional anticoagulants

---

Review Article

Author Details : Sunil Chaudhry*

Volume : 10, Issue : 1, Year : 2022

Article Page : 17-21

https://doi.org/10.18231/j.jpbs.2022.004

Suggest article by email

Get Permission

---

Abstract

The past 15 years have seen increased usage of factor Xa inhibitor anticoagulants such as rivaroxaban, apixaban, and edoxaban, along with dabigatran (competitive direct thrombin inhibitor), which have been used increasingly in various clinical settings, for the prevention and treatment of thrombosis. In many ways Factor Xa inhibitors have replaced the use of warfarin, which requires prudent monitoring . Factor Xa inhibitor short half-lives, compared to warfarin’s, provide some assurance that the drug concentrations will decline rapidly when therapy is discontinued in patients with normal renal function. Good haemostatic efficacy was achieved in 83% patients on apixaban and 80% patients on rivaroxaban . Major bleeding events in nonvalvular atrial fibrillation patients on rivaroxaban were 3.6% per year and on apixaban were 2.13% per year in respective landmark trials conducted. Some drawbacks of Factor Xa inhibitors include uncertainty about dosing in some patient populations (eg, renal dysfunction, marked extremes of body weight), and their higher drug cost.

Keywords: Anticoagulant, Pulmonary embolism, Venous thromboembolism

How to cite : Chaudhry S, Factor Xa inhibitors, Era to replace traditional anticoagulants. J Pharm Biol Sci 2022;10(1):17-21

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.